Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Day One Biopharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Aprea Therapeutics
Elevation Oncology
Stanford University
AstraZeneca
Merck Sharp & Dohme LLC
VA Office of Research and Development
Eli Lilly and Company
ADC Therapeutics S.A.
Pfizer
Pfizer
Rutgers, The State University of New Jersey
pharmaand GmbH
Genmab
Revolution Medicines, Inc.
Pfizer
Incyte Corporation
Seagen Inc.
Gilead Sciences
Bayer
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Dartmouth-Hitchcock Medical Center
University of Kansas Medical Center
GlaxoSmithKline
Roswell Park Cancer Institute
Amgen
National Institutes of Health Clinical Center (CC)
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
Sandoz
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
Altor BioScience